Breast Cancer

HER2 antibodies have revolutionized breast cancer treatment by targeting the overexpressed HER2 protein in tumors, which drives aggressive cancer growth. Breakthroughs in monoclonal antibodies and antibody-drug conjugates not only enhance treatment efficacy but also expand options for various HER2 expressions. Challenging resistance and understanding combination therapies further amplify potential outcomes for patients worldwide. Understanding HER2 […]